
MPS VI, Severe Form: ARSB Testing, ERT and Transplant
Galsulfase infusions and stem cell transplantation are the options described once ARSB testing confirms the arylsulfatase B deficiency behind MPS VI symptoms.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Galsulfase infusions and stem cell transplantation are the options described once ARSB testing confirms the arylsulfatase B deficiency behind MPS VI symptoms.

Genetic and epigenetic changes, drug transport and the tumor microenvironment all feed resistance in multiple myeloma; FISH, karyotyping and NGS are explained.

Caused by FKRP mutations and inherited in an autosomal recessive pattern, MDDGB5 brings muscle weakness, joint contractures, respiratory and heart problems.

Symptoms in this rare variant improve with acetazolamide, and CLCN1 gene testing can confirm the diagnosis and pick out carriers within a family.

Mutations in GDAP1 impair mitochondrial function in peripheral nerves, bringing muscle weakness, sensory loss and partial vocal cord paralysis.

Abnormal sweating, cardiovascular instability and joint deformities accompany sensory loss in HSAN IC, and KIF1A sequencing gives a definitive diagnosis.

Cholesterol that cells cannot clear brings neurological decline and enlarged liver and spleen; DNA analysis diagnoses NPC1 when biochemical tests are unclear.

Children and adolescents with this form face movement difficulty and progressive neurological decline; NPC1 testing confirms cases and flags at-risk siblings.